Indaptus Therapeutics
INDP
15 hedge funds and large institutions have $1.31M invested in Indaptus Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
14.67% less ownership
Funds ownership: 20.73% → 6.07% (-15%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
98% less capital inflows, than outflows
Capital inflows: $80.7K | Capital outflows: $3.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$54.7K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.2K |
| 3 |
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$8.04K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$4.76K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$78 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stratos Wealth Partners
Beachwood,
Ohio
|
-$3.24M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$169K |
| 3 |
United Capital Financial Advisors
Irving,
Texas
|
-$60K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| 5 |
Morgan Stanley
New York
|
-$78 |
INDP Hedge Fund Activity: Q2 2022 in Review
15 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q2 2022, worth a combined $1.31M — down 81% from $6.81M a quarter earlier.
Fund positioning in INDP was balanced in Q2 2022: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $54.7K. The largest seller was Stratos Wealth Partners, cutting an estimated $3.24M.
- 15 institutional investors held Indaptus Therapeutics (INDP) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $1.31M of Indaptus Therapeutics stock for Q2 2022, down 81% quarter-over-quarter.
- 4 funds opened new Indaptus Therapeutics positions in Q2 2022 and 4 closed out, a net change of 0 holders.
- The largest Indaptus Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $54.7K added.
- The largest Indaptus Therapeutics seller in Q2 2022 was Stratos Wealth Partners, an estimated $3.24M sold.
Based on aggregated 13F filings for Q2 2022.